This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BioMarin Pharmaceutical Inc.
Drug Names(s): Phenoptin, sapropterin dihydrochloride, 6R-BH4, BH4, SUN-0588, Biopten [Japan], Sapropterin [EU]
Kuvan (6R-BH4) is an enzyme cofactor that is a second generation, proprietary oral form of naturally occurring tetrahydrobiopterin (BH4). BH4 is the cofactor for the enzyme phenylalanine hydroxylase, which breaks down phenylalanine.
In phenylketonuria patients, phenylalanine hydroxylase activity is absent or deficient.
Revenue splits for this drug are BioMedTracker estimates.
U.S. historical revenue excludes the EU royalty revenue included in BioMarin's reported sales for Kuvan. WW historical revenue comprises U.S. sales, EU sales and estimates of Japan sales based on the 15% royalty earned from Daiichi.
Daiichi Suntory and BioMarin
Kuvan was discovered by Daiichi Suntory Pharma and is sold in Japan by Maruho Co., Ltd. as Biopten. In Japan, BioMarin will receive milestone payments as well as double-digit royalties on net sales of BH4 for PKU from Asubio Pharma (a subsidiary of Daiichi Sankyo).
BioMarin and Merck KGaA
BioMarin and Merck Eprova (a subsidiary of Merck KGaA) entered into an agreement for equal sharing of costs for clinical development and manufacturing of Kuvan. BioMarin has the worldwide intellectual property right and will pay royalties on sale of phenoptic products to Merck Eprova. Biomarin also has right of first refusal to...See full deal structure in Biomedtracker
Partners: Merck KGaA Daiichi Sankyo Co., Ltd.
Additional information available to subscribers only: